The processes of intestinal growth and differentiation are essential to the maintenance of normal gut function. Derangements in gut mucosal growth and differentiation result in diarrhea, malabsorption, and altered barrier function. Thyroid hormone (T3) is one of the most potent regulators of intestinal epithelial growth and differentiation, but its mechanism of action in the GI tract is largely unknown. This research proposal is designed to elucidate the molecular mechanisms by which T3 exerts its profound effects upon GI mucosal structure and function. Both in vivo and in vitro studies have demonstrated that T3 has two major effects upon the small intestinal epithelium (1) induction of crypt cell hyperplasia and (2) alteration in the pattern of enterocyte gene expression, e.g., increased intestinal alkaline phosphatase (IAP) expression. The effects of T3 on target tissues are generally mediated through binding to a nuclear receptor protein which interacts directly with DNA cis-elements (TRE) within specific T3-responsive genes. Multiple forms of the T3 receptor (TR) are encoded by either the alpha or beta cerbA genes, including a non-hormone binding variant, c-erbA alpha-2, which is thought to inhibit T3 action. Since cellular T3-responsiveness is dependent upon the relative abundance of the various TRs, we will use in situ hybridization and crypt-villus separation techniques to determine the cell type-specific patterns of TR expression within the small intestinal mucosa. They have established TR-transfected HT-29 cells (HT-29TR) as an excellent in vitro model to study the T3 effects on intestinal epithelial cells. HT-29TR cells will be treated with T3 to examine the nature of the growth response, e.g., 3H thymidine incorporation, proto-oncogene induction, and gel shift assays to identify a nuclear complex with the c-fox serum response element. Direct comparisons will be made with the well characterized crypt cell growth factor, EGF. Sodium butyrate-treated HT-29TR cells will then be used as a model of villus enterocytes and the T3 effects upon IAP gene expression examined. Transient transfection experiments with IAP reporter gene constructs will enable them to identify the important DNA cis-regulatory elements. Finally, DNAse 1 footprinting and gel shift assays will be performed to more precisely define the relevant DNA-protein interactions underlying T3-regulated gene expression. The proposed studies will enhance the understanding of the role that T3 plays in regards to intestinal mucosal structure and function, and should have broader implications for the biology of development and neoplasia. It is hoped that the studies will identify potential therapeutic targets which could be used in the future to maintain gut integrity during critical illness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK050623-02
Application #
2518510
Study Section
Surgery and Bioengineering Study Section (SB)
Project Start
1996-09-01
Project End
2000-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Malo, Madhu S; Moaven, Omeed; Muhammad, Nur et al. (2014) Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. Am J Physiol Gastrointest Liver Physiol 306:G826-38
Alam, Sayeda Nasrin; Yammine, Halim; Moaven, Omeed et al. (2014) Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg 259:715-22
Moss, Angela K; Hamarneh, Sulaiman R; Mohamed, Mussa M Rafat et al. (2013) Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol 304:G597-604
Kaliannan, Kanakaraju; Hamarneh, Sulaiman R; Economopoulos, Konstantinos P et al. (2013) Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A 110:7003-8
Nucera, Carmelo; Nehs, Matthew A; Nagarkatti, Sushruta S et al. (2011) Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309
Ramasamy, Sundaram; Nguyen, Deanna D; Eston, Michelle A et al. (2011) Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis 17:532-42
Chen, Kathryn T; Malo, Madhu S; Beasley-Topliffe, Laura Kline et al. (2011) A role for intestinal alkaline phosphatase in the maintenance of local gut immunity. Dig Dis Sci 56:1020-7
Ebrahimi, Farzad; Malo, Madhu S; Alam, Sayeda Nasrin et al. (2011) Local peritoneal irrigation with intestinal alkaline phosphatase is protective against peritonitis in mice. J Gastrointest Surg 15:860-9
Chen, Kathryn T; Malo, Madhu S; Moss, Angela K et al. (2010) Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol 299:G467-75
Malo, M S; Alam, S Nasrin; Mostafa, G et al. (2010) Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59:1476-84

Showing the most recent 10 out of 33 publications